Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Sep 19, 2023 (filed on Sep 21, 2023)Insider Name:Mercer PatrickOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:115,000Price:--
-
Jun 14, 2023 (filed on Jun 15, 2023)Insider Name:Shuda ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:39,267Price:$1.91
-
Jun 14, 2023 (filed on Jun 15, 2023)Insider Name:Ludlum KenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:39,267Price:$1.91
-
Jun 14, 2023 (filed on Jun 15, 2023)Insider Name:Grove Robert EarleOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:39,267Price:$1.91
-
Jun 14, 2023 (filed on Jun 15, 2023)Insider Name:Huss Beverly AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:39,267Price:$1.91
-
Jun 14, 2023 (filed on Jun 15, 2023)Insider Name:Devi NandiniOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:39,267Price:$1.91
Filings by filing date
-
Sep 19, 2023 (filed on Sep 21, 2023)Insider Name:Mercer PatrickOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:115,000Price:--
-
Jun 14, 2023 (filed on Jun 15, 2023)Insider Name:Shuda ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:39,267Price:$1.91
-
Jun 14, 2023 (filed on Jun 15, 2023)Insider Name:Ludlum KenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:39,267Price:$1.91
-
Jun 14, 2023 (filed on Jun 15, 2023)Insider Name:Grove Robert EarleOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:39,267Price:$1.91
-
Jun 14, 2023 (filed on Jun 15, 2023)Insider Name:Huss Beverly AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:39,267Price:$1.91
-
Jun 14, 2023 (filed on Jun 15, 2023)Insider Name:Devi NandiniOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:39,267Price:$1.91
News
Biz Brief
Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1212 Terra Bella Ave MOUNTAIN VIEW CA 94043-1824 |
Tel: | N/A |
Website: | https://www.iridex.com |
IR: | See website |
Key People | ||
David I. Bruce President, Chief Executive Officer, Director | Fuad Ahmad Interim Chief Financial Officer | Patrick Mercer Chief Operating Officer |
Business Overview |
IRIDEX Corporation is an ophthalmic medical technology company. It develops and commercializes products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probes products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces. |
Financial Overview |
For the fiscal year ended 30 December 2023, IRIDEX Corp revenues decreased 9% to $51.9M. Net loss increased 27% to $9.6M. Revenues reflect United States segment decrease of 11% to $26.1M, Rest of the Americas segment decrease of 33% to $2.1M. Higher net loss reflects Selling expenses increase of 17% to $7.9M (expense), Stock-based Compensation in R&D increase of 40% to $217K (expense). |
Employees: | 111 as of Dec 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $40.75M as of Dec 30, 2023 |
Annual revenue (TTM): | $51.87M as of Dec 30, 2023 |
EBITDA (TTM): | -$8.91M as of Dec 30, 2023 |
Net annual income (TTM): | -$9.57M as of Dec 30, 2023 |
Free cash flow (TTM): | -$6.85M as of Dec 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 16,252,813 as of Mar 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |